Certificate PL-26-00210 · Hexarelin 5 mg Nasal Spray · lot PL-2610-094
VerifyCertificate page
PrymaLab
PrymaLab
PrymaLab Analytical · In-house laboratory
3705 Music Branch Rd, Ashland, KY 41102 · +1 (606) 465-9063 · prymalab.net
Certificate no.
PL-26-00210
Verification key
9GY8L9LE
Scan or enter both at
prymalab.net/testing/verify

Certificate of Analysis · Lot release

Hexarelin 5 mg Nasal Spray

Lot PL-2610-094 · Solution · Label claim 5 mg per bottle
Tested in-house by PrymaLab
In-house analytical result,
not an independent third-party test
Lot / batch number
PL-2610-094
Date made
2026-10-05
Date of analysis
2026-10-06
Date issued
2026-10-12
Retest / expiry
2028-10-05
Units in lot / sampled
236 / 2
Storage
—
Certificate type
Lot COA, 2 pages
Compound
Hexarelin
Examorelin; growth hormone-releasing hexapeptide
CAS number
140703-51-1
Molecular formula
C47H58N12O6
Theoretical mass (avg.)
887.01 Da
Sequence
His-D-2MeTrp-Ala-Trp-D-Phe-Lys-NH2
Purity · RP-HPLC, area %
99.61%
Specification ≥ 99.0% • main peak at 10.45 min
Identity · Observed Mass
887.03 Da
Theoretical 887.01 Da • +0.02 Da (23 ppm)
Overall conclusion
PASS
Meets every specification for the tests performed
TestMethodSpecificationResultConclusion
Identity (mass)LC-MS, ESI positiveTheoretical ± 1.0 Da887.03 DaPASS
PurityRP-HPLC, UV 214 nm, area%≥ 99.0%99.61%PASS
Largest impurityRP-HPLC, area%≤ 1.0%0.25% (RT 11.10)PASS
Assay (label claim)Assay vs label claim4.75–5.25 mg/bottle5.11 mg/bottlePASS
Bacterial endotoxinLAL, kinetic≤ 5.0 EU/mg0.192 EU/mgPASS
Aerobic count (TAMC)USP <61>< 10 CFU/mL< 10 CFU/mLPASS
Yeast & mold (TYMC)USP <61>< 10 CFU/mL< 10 CFU/mLPASS
E. coliUSP <62>AbsentAbsentPASS

1HPLC chromatogram

Data file: PL-2610-094-HPLC.raw · Column C18, 150 × 4.6 mm · UV 214 nm
0.01%0.1%1%10%100%8910111213Retention time (min) · stick height = area % (log scale)99.61% · 10.45 min0.02% †0.25% †0.12% †
Peak plot drawn from the integrated peak table (area %, log scale); it is not the instrument trace, which is retained in PL-2610-094-HPLC.raw. † Nominal reference retention time for the assigned impurity; the main-peak RT is observed in this lot.
PrymaLab
PrymaLab
Certificate of Analysis · continued
Hexarelin 5 mg Nasal Spray · Lot PL-2610-094 · Certificate PL-26-00210
Lot PL-2610-094
Method, peak table and approval

2HPLC method · PL-2610-094-HPLC.raw

Instrument
Waters Alliance e2695
Data System
Empower 3
Detector
UV absorbance
Detection Wavelength
214 nm
Column
C18, 150 × 4.6 mm, 3.5 µm
Mobile Phase A
0.1% TFA in water
Mobile Phase B
0.1% TFA in MeCN
Gradient
5–95% B over 25 min (linear)
Flow Rate
1.0 mL/min
Column Temperature
40 °C
Injection Volume
10 µL

3Gradient program

Time (min)% A% B
0.0955
25.0595

4Peak table

PeakRT (min)AreaArea %
19.20 †—0.02
210.45—99.61
311.10 †—0.25
411.80 †—0.12
Total—100.00
Peaks: 1 tryptophan oxidation product; 2 main peak (Hexarelin); 3 deamidation product; 4 truncated sequence · Area % from the integrated peak table (absolute areas are not part of the lot-release export) · † nominal reference RT for the assigned impurity · Purity = main peak area ÷ total integrated area × 100, to two decimals; main peak shaded.

5Identity by mass spectrometry

Instrument
Waters SQD
Ionization / Mode
ESI, positive
Reference m/z (charge)
888.02 (M+H)+
Deconvoluted Mass
887.03 Da
Theoretical Mass
887.01 Da
Difference
+0.02 Da (23 ppm)
Data File
PL-2610-094-MS.d
Acceptance
Within ± 1.0 Da

6Additional tests

TestPerformed byDateReport / file
Assay vs label claimPrymaLab Analytical2026-10-06—
Endotoxin (LAL, kinetic)PrymaLab Analytical2026-10-06—
Microbial limits (USP <61>/<62>)PrymaLab Analytical2026-10-12—
A test with no row here was not performed on this lot. Outside-laboratory reports, when used, are attached and named below.

7Review and approval

D. Reynolds
Analyst · performed the testing
Date: 2026-10-12
S. Calloway
Reviewer · checked against raw data
Date: 2026-10-12
M. Phelps
Lab Director · approved for release
Date: 2026-10-12